anonymous
Guest
anonymous
Guest
The problems are as follows
- Our science is lacking and medical needs an overhaul. Failure after Failure
- IC plan..blows
- Reimbursement
- And our Drug pricing policy is out of touch with reality.
- Don’t understand our customers even with all the MBAs in leadership or marketing.
- we are disease niche company not a SOC company anymore, but leadership mindset isn’t in sync.
- Our science is lacking and medical needs an overhaul. Failure after Failure
- IC plan..blows
- Reimbursement
- And our Drug pricing policy is out of touch with reality.
- Don’t understand our customers even with all the MBAs in leadership or marketing.
- we are disease niche company not a SOC company anymore, but leadership mindset isn’t in sync.